论文部分内容阅读
目的探讨2型糖尿病(type 2 diabetes mellitus,T2DM)患者慢性炎症状态以及服用阿卡波糖对其的影响。方法选取住院的糖尿病患者68例随机分为两组:A组予阿卡波糖50mg3次/d口服,B组不给阿卡波糖,其他治疗相同,应用ELISA方法测定血浆中单核细胞趋化蛋白-1(MCP-1)和肿瘤坏死因子-α(TNF-α)水平。结果干预治疗后两组MCP-1及TNF-α明显减低(P<0.05),与B组比较,A组下降趋势更明显(P<0.05)。结论 2型糖尿病是一种慢性低度炎症性疾病,阿卡波糖干预治疗可降低MCP-1及TNF-α炎症因子水平。
Objective To investigate the chronic inflammatory state of type 2 diabetes mellitus (T2DM) patients and the effect of acarbose on it. Methods Sixty-eight inpatients with diabetes mellitus were randomly divided into two groups: group A was treated with acarbose 50 mg 3 times / d orally, group B was not given acarbose, and the other treatments were the same. ELISA was used to measure the monocyte tendency in plasma (MCP-1) and tumor necrosis factor-α (TNF-α) levels in serum. Results The levels of MCP-1 and TNF-α in the two groups were significantly decreased after intervention (P <0.05). Compared with group B, the decline trend of group A was more obvious (P <0.05). Conclusion Type 2 diabetes mellitus is a chronic, low-grade inflammatory disease. Acarbose intervention can reduce the levels of MCP-1 and TNF-α.